Back to Market Feed

Product Information

MIGRAINE 250-250-65 MG GELTAB is a generic product labeled by Cardinal Health, priced at $0.0649 per EA under NDC 70000061101. Its NADAC has been published 186 times since Feb 1, 2023.

FDA first approved this application on Nov 26, 2001.

MIGRAINE 250-250-65 MG GELTAB

acetaminophen, aspirin, caffeine
$0.0649per EA
OTC

Strength

250; 250; 65 mg/1; mg/1; mg/1

Manufacturer

Cardinal Health

NDC

70000061101

Classification

Generic

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Approval Type

Generic (ANDA)

FDA Application

ANDA075794

FDA Approved

11/26/2001

On Market Since

8/8/2022

Pharmacological Classes

Anti-Inflammatory Agents
Non-Steroidal
Central Nervous System Stimulant
Central Nervous System Stimulation
Cyclooxygenase Inhibitors
Decreased Platelet Aggregation
Decreased Prostaglandin Production
Methylxanthine
Nonsteroidal Anti-inflammatory Drug
Platelet Aggregation Inhibitor
Xanthines

Price Statistics

The NADAC for MIGRAINE 250-250-65 MG GELTAB has been published 186 times since Feb 1, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price$0.0649 per EA
All-time high$0.0698 (Sep 11, 2024)
All-time low$0.0584 (Apr 17, 2024)
52-week high$0.0691
52-week low$0.0635
Median price$0.0642
Average price$0.0642
Largest weekly change+11.2% (Oct 18, 2023)
Weeks tracked186
Tracking sinceFeb 1, 2023

Price History

1W

-2.6%

1M

-2.6%

3M

-3.3%

6M

+1.9%

1Y

-5.4%

3Y

+9.6%

5Y

N/A

All

+2.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the acetaminophen, aspirin, caffeine market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient and strength in a comparable dosage form.

Related Drugs

Same classification

MINIPRIN EC 81 MG TABLET
Generic
49483033010•Time-Cap Labs Inc.
$0.0118
per EA
MINIPRIN EC 81 MG TABLET
Generic
49483033012•Time-Cap Labs Inc.
$0.0118
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035203•Chain Drug Marketing Association
$0.0121
per EA
QC ASPIRIN 325 MG TABLET
Generic
63868035210•Chain Drug Marketing Association
$0.0121
per EA
ST. JOSEPH ASPIRIN EC 81 MG TB
Generic
69536018112•Foundation Consumer Healthcare LLC
$0.0139
per EA
ASPIRIN EC 81 MG TABLET
Generic
00536123441•Rugby Laboratories
$0.0146
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904675180•Major Pharmaceuticals
$0.0146
per EA
ASPIRIN EC 81 MG TABLET
Generic
00904678370•Major Pharmaceuticals
$0.0146
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059848•AmerisourceBergen
$0.0146
per EA
GNP ASPIRIN EC 81 MG TABLET
Generic
46122059887•AmerisourceBergen
$0.0146
per EA

Frequently asked questions

What is the NADAC price of MIGRAINE 250-250-65 MG GELTAB?

The current National Average Drug Acquisition Cost (NADAC) for MIGRAINE 250-250-65 MG GELTAB, manufactured by Cardinal Health, is $0.0649 per EA (NDC 70000061101), effective Aug 19, 2026.

How has the price of MIGRAINE 250-250-65 MG GELTAB changed over time?

Over the history we have for it, the NADAC for MIGRAINE 250-250-65 MG GELTAB has held within roughly two percent of its current level. It has been tracked across 186 weekly CMS publications since Feb 1, 2023.

What are the highest and lowest recorded NADAC prices for MIGRAINE 250-250-65 MG GELTAB?

Since Feb 1, 2023, the NADAC for MIGRAINE 250-250-65 MG GELTAB has ranged from a low of $0.0584 (Apr 17, 2024) to a high of $0.0698 (Sep 11, 2024), with a median of $0.0642 per EA.

Are there cheaper alternatives to MIGRAINE 250-250-65 MG GELTAB?

No other NADAC-published product currently shares the active ingredient and strength of MIGRAINE 250-250-65 MG GELTAB in a comparable dosage form, so no direct lower-cost alternative is listed.

Who manufactures MIGRAINE 250-250-65 MG GELTAB?

MIGRAINE 250-250-65 MG GELTAB (NDC 70000061101) is labeled by Cardinal Health, and CMS classifies it as a generic product.